---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-043158"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2024-04-03T23:59:59+00:00"
generated_at: "2026-06-04T02:48:27.373386+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Iovance settles derivative suit over director compensation; $600k fee, option cancellations

## Summary
- Iovance cancels 12,796 (2019), 11,731 (2020), 8,603 (2021) options to non-employee directors; awards reduced below 75th peer percentile.
- Governance reforms cap director comp at 75th percentile through 2027, limit options to 60% of equity grants, require annual comp consultant review.
- Iovance pays $600,000 for plaintiff attorney fees (court approval required); no admission of wrongdoing by defendants.
- Settlement hearing scheduled for July 11, 2024; if approved, derivative action dismissed with prejudice.
- Stockholders may object by July 1, 2024 with proof of ownership and grounds; otherwise barred from contesting settlement.

## SEC filing metadata
- accession: 0001104659-24-043158
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2024-04-03T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465924043158/0001104659-24-043158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465924043158/tm2410795d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-043158
- JSON: https://secwatch.observer/filing/0001104659-24-043158.json
- Plain text: https://secwatch.observer/filing/0001104659-24-043158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.